Global Information
회사소개 | 문의 | 위시리스트

핵의학용 방사성 동위원소(RI) 시장 : 성장, 동향, 예측(2019-2024년)

Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence LLP
발행일 2019년 03월 상품 코드 661020
페이지 정보 영문 119 Pages
가격
US $ 4,250 ₩ 5,121,000 PDF by E-mail (Single User License)
US $ 4,500 ₩ 5,422,000 PDF by E-mail (Team License: Up to 5 Users)
US $ 7,000 ₩ 8,435,000 PDF by E-mail (Site License)
US $ 8,750 ₩ 10,543,000 PDF by E-mail (Corporate License)


핵의학용 방사성 동위원소(RI) 시장 : 성장, 동향, 예측(2019-2024년) Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 03월 페이지 정보 : 영문 119 Pages

세계의 핵의학용 방사성 동위원소(RI) 시장을 조사했으며, 종류·응용 분야·지역별 시장 규모 추이와 예측, 시장 동향, 성장 촉진요인 및 저해요인·기회·과제 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재의 시장 시나리오
  • Five Forces 분석
    • 구매자의 협상력
    • 공급 기업의 협상력
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제6장 성장 촉진요인 및 저해요인, 기회, 과제

  • 시장 성장 촉진요인
    • 암 및 심장병 발증률 상승
    • 핵의학의 응용 확대
    • SPECT 및 PET의 용도 확대
    • 건강하게 대한 환자의 의식 향상
  • 시장 성장 저해요인
    • 상환제도의 복잡성
    • 규제상 과제
  • 시장 기회
  • 주요 과제

제7장 시장 세분화

  • 종류별
    • Technetium-99m(Tc-99m)
    • Thallium-201(Tl-201)
    • Iodine(I-123)
    • Gallium-67(Ga-67)
    • Fluorine-18
    • Rubidium-82(Rb-82)
    • 기타
  • 응용 분야별
    • 종양
    • 심장병
    • 림프종
    • 갑상선
    • 신경
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 경쟁 구도

  • 인수합병(M&A) 분석
  • 합의, 협력, 제휴
  • 신제품 발매

제9장 주요 기업

  • Agfa-Gevaert Group
  • Braco
  • Cardiarc Ltd
  • Cardinal Health Inc.
  • CMR Naviscan(Gamma Medica Inc.)
  • Curium
  • Digirad Corporation
  • GE Healthcare
  • Nordion(Canada) Inc.
  • NTP Radioisotopes SOC Ltd
  • Positron Corp.
  • Segami Corporation
  • Siemens Healthcare

제10장 시장 전망

LSH 18.07.18

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Market Overview

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves' disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Scope of the Report

As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

North America captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Widening Applications of Nuclear Medicine
    • 4.2.3 Increasing SPECT and PET Applications
    • 4.2.4 Increasing Patient Awareness for Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Complications
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Radioisotopes
    • 5.1.1 Technetium-99m (Tc-99m)
    • 5.1.2 Thallium-201 (Tl-201)
    • 5.1.3 Iodine (I-123)
    • 5.1.4 Fluorine-18
    • 5.1.5 Rubidium-82 (Rb-82)
    • 5.1.6 Iodine-131 (I-131)
    • 5.1.7 Lutetium-177 (Lu-177)
    • 5.1.8 Radium-223 (Ra-223) & Alpharadin
    • 5.1.9 Actinium-225 (Ac-225)
    • 5.1.10 Others
  • 5.2 Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Lymphoma
    • 5.2.4 Thyroid
    • 5.2.5 Neurology
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agfa-Gevaert Group
    • 6.1.2 Cardiarc Ltd
    • 6.1.3 Digirad Corporation
    • 6.1.4 CMR Naviscan (Gamma Medica Inc.)
    • 6.1.5 GE Healthcare
    • 6.1.6 Positron Corp.
    • 6.1.7 Segami Corporation
    • 6.1.8 Siemens Healthcare GmBH
    • 6.1.9 Nordion (Canada) Inc.
    • 6.1.10 NTP Radioisotopes SOC Ltd
    • 6.1.11 Bracco S.p.A
    • 6.1.12 Cardinal Health Inc.
    • 6.1.13 Curium

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q
 
BCC Research